--------- Forwarded Message ----------
  April 2007 • Clinical Trial Information for the Parkinson's 
Community 

see the website at : www.pdtrials.org

New Clinical Trials

Ceregene Presents Data From Phase 1 Trial of CERE-120 Demonstrating 
Improved Motor Function in Parkinson's Patients

FDA Takes Pergolide Off US Market

The 2007 Unity Walk To Be Held on April 28th

Help Inform Others About Clinical Trials!



Resources

Do You Have Questions About Clinical Research? Order A Free Clinical 
Trial Informational Brochure 

Greetings!
Thank you for signing up to receive the PDtrials Bulletin. This 
regular email newsletter provides you with information on Parkinson's 
disease clinical trials that are actively looking for participants, 
as well as news on Parkinson's research and treatments. 
PDtrials is a collaborative initiative of Parkinson's organizations 
and is dedicated to increasing awareness and education about 
Parkinson's clinical trials. Please contact us if you would like more 
information about this effort. 

New Clinical Trials
Parkinson Associated Risk Study (PARS): Evaluating Potential 
Screening Tools for Parkinson's Disease - 
The PARS study is the largest long-term study in the United States of 
relatives of individuals with Parkinson's disease (PD). It will 
follow a group of 300 individuals over a two-year period to determine 
whether specific tests are able to predict who may be at increased 
risk for developing PD. The goal of the PARS study is to better 
understand who is at risk for PD so that it can ultimately be 
prevented before it starts. Learn more

Study of the Effect of Long-Lasting Sequence Movements in Early-Stage 
and Advanced Parkinson's Disease - 
This study will explore sequence effect, a fatigue or tiredness 
commonly seen in persons with PD after they have been doing the same 
thing for a while. The study will use a new device called a modified 
peg board test to measure whether anti-parkinsonian medications 
(levodopa/carbidopa or dopamine) and repetitive transcranial magnetic 
stimulation (rTMS) of the brain can improve the symptoms of sequence 
effect. Learn more

A Study of a New Drug, Azilect, Alone or in Combination Therapy for 
Parkinson's Disease - 
The primary goal of this study is to identify the earliest scheduled 
visit at which the symptomatic effect of a new drug, Azilect, as 
initial monotherapy, can be demonstrated. The secondary goal of this 
study is to characterize the effectiveness of Azilect in a usual 
community neurological practice by assessing investigator and 
participant satisfaction. This study is now only enrolling persons 
not currently receiving any therapy for their PD. Learn more
Study of CERE-120 in People with Parkinson's Disease - 
The purpose of this study is to determine whether CERE-120 is a safe 
and effective treatment for people with PD. CERE-120 is a gene 
transfer agent comprised of an adeno-associated virus (AAV2) carrying 
the gene for neurturin (NTN). NTN is a naturally occurring protein 
very similar to GDNF (Glial Derived Neurotrophic Factor), whose role 
is to improve the health and function of degenerating dopamine-
secreting neurons and to keep them alive and functioning normally. 
Learn more

NET-PD LS-1 Creatine in Parkinson's Disease, Recruiting 1,720 
Participants - 
NET-PD is a large NIH-sponsored effort to find drugs that slow the 
progression of PD. Symptoms of PD may include tremor, rigidity or 
stiffness of the limbs and trunk, slowness of movement, and impaired 
balance and coordination. These problems occur because as PD worsens, 
some of the brain cells that control body movement die. This study 
will determine if creatine, an investigational drug, is able to slow 
the progression of PD. Learn moreView All Clinical Trials

Ceregene Presents Data From Phase 1 Trial of CERE-120 Demonstrating 
Improved Motor Function in Parkinson's Patients
Ceregene, Inc., a biopharmaceutical company, today presented long 
term follow-up data from a Phase 1 clinical trial of CERE-120, a gene 
therapy product in development for the treatment of Parkinson's 
disease, demonstrating a 36 percent reduction in Parkinson's symptoms 
at 12 months after administration. CERE-120 was also shown to be well 
tolerated in this study.Read more

FDA Takes Pergolide Off US Market
The FDA has announced that the companies that manufacture and 
distribute pergolide have agreed to withdraw this drug from the 
market due to the potential for heart valve damage. Pergolide is a 
member of a class of drugs known as dopamine agonists and is used 
with levodopa and carbidopa to manage the signs and symptoms (tremors 
and slowness of movement) of PD.Read more

The 2007 Unity Walk To Be Held on April 28th
The Parkinson's Unity Walk is the largest grassroots fundraiser for 
Parkinson's research in the community. Since 1994, families, friends, 
caregivers, and major Parkinson's foundations have gathered once a 
year to unify with the common goal of finding a cure for Parkinson's 
disease.Read more

Help Inform Others About Clinical Trials!
Do you find the information in this email bulletin and on 
PDtrials.org to be a helpful resource? If so, won't you take a moment 
and send this email bulletin to others?
Just click on the "Send" button located on the top left of this page 
and enter the email addresses of friends, family, support group 
members, and others who you think would like to learn more about 
clinical studies.

Copyright (c) 2007 PDtrials. All rights reserved.    
Forward email

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn